Spero Therapeutics announced its financial results for the second quarter ended June 30, 2025, on August 12, 2025. The company highlighted the significant milestone achieved during the quarter with the tebipenem Phase 3 PIVOT-PO trial meeting its primary endpoint.
The company is actively working with GSK to complete the Phase 3 data analysis and prepare the data package for submission to the FDA. This progress is crucial for advancing tebipenem HBr, which is being developed as an oral carbapenem for complicated urinary tract infections.
Spero reiterated its cash runway, stating that existing cash and expected non-contingent GSK milestone payments, including the final $23.8 million payment in Q3 2025, are anticipated to fund operations into Q2 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.